Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.


NDAQ:PMN - Post by User

Comment by farmerjaneon Apr 13, 2021 8:18pm
216 Views
Post# 32990270

RE:Sharp drop

RE:Sharp drop No news for a couple of years, just PP's, and the other stuff is just fluff nothing material. As you can see the only halt trading these characters have done over 5-6 years is a PP, kind of sums things up. Not expecting anything out of Eugene or Elliot they've repeatedly missed corporate objectives year after year, long past anyone can seriously defend. Fully expect the stock to retreat, they are set up with wages for the first quater of 2022 with the latest PP. As for the Alzheimers blood testing last year with Toronto Memory announced in February 2020 a 6 month program not a word, Serology hoopla everyone knows except for RC what a joke that is. You have to follow the money in the PP's to understand where the PP's have gone to and why the stock goes to 20-25 then down to 10. Simple  pattern over the last few years.
<< Previous
Bullboard Posts
Next >>